Patents Assigned to Promics Pty Limited
-
Publication number: 20130005644Abstract: The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions.Type: ApplicationFiled: January 12, 2012Publication date: January 3, 2013Applicant: PROMICS PTY LIMITEDInventors: David FAIRLIE, Stephen Maxwell Taylor, Angela Monique Finch, Allan Wong
-
Publication number: 20120302493Abstract: The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages. The compounds of the invention are both potent and selective, and are useful in the treatment of a variety of inflammatory conditions.Type: ApplicationFiled: February 2, 2012Publication date: November 29, 2012Applicant: Promics PTY LimitedInventors: Stephen Maxwell Taylor, Ian Alexander Shiels, David Fairlie, Darren March, Michael W. Whitehouse
-
Patent number: 7919459Abstract: This invention relates to the use of an antagonist of a G protein-coupled receptor in the prevention and/or treatment of fibrosis, such as the treatment of fibrosis associated with myocardial infarction or diabetes or certain pulmonary conditions. In a preferred embodiment, the antagonist is a C5a receptor antagonist, more preferably a cyclic peptide antagonist of the C5a receptor. In particular, the invention provides a method of prevention, treatment or alleviation of a fibrotic condition, comprising the step of administering an effective amount of an antagonist of a G protein-coupled receptor to a subject in need of such treatment.Type: GrantFiled: May 30, 2007Date of Patent: April 5, 2011Assignee: Promics Pty LimitedInventors: Stephen Maxwell Taylor, Ian Alexander Shiels, Lindsay Charles Brown, Michael Wellesley Whitehouse
-
Publication number: 20100331236Abstract: The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages. The compounds of the invention are both potent and selective, and are useful in the treatment of a variety of inflammatory conditions.Type: ApplicationFiled: July 14, 2009Publication date: December 30, 2010Applicants: PROMICS PTY LIMITED, UNIQUEST PTY LIMITEDInventors: Stephen Maxwell Taylor, Ian Alexander Shiels, David Fairlie, Darren March, Michael Whitehouse
-
Publication number: 20100267639Abstract: This invention relates to methods of treatment of osteoarthritis, and especially to treatment of this condition with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes and macrophages. Particularly preferred compounds for use in the invention are disclosed.Type: ApplicationFiled: February 9, 2010Publication date: October 21, 2010Applicant: PROMICS PTY LIMITEDInventors: Ian Alexander Shiels, David Fairlie
-
Patent number: 7659246Abstract: This invention relates to methods of treatment of osteoarthritis, and especially to treatment of this condition with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes and macrophages. Particularly preferred compounds for use in the invention are disclosed.Type: GrantFiled: October 15, 2003Date of Patent: February 9, 2010Assignee: Promics Pty LimitedInventors: Ian Alexander Shiels, David Fairlie
-
Patent number: 7579432Abstract: The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages. The compounds of the invention are both potent and selective, and are useful in the treatment of a variety of inflammatory conditions.Type: GrantFiled: October 17, 2002Date of Patent: August 25, 2009Assignee: Promics Pty LimitedInventors: Stephen Maxwell Taylor, Ian Alexander Shiels, David Fairlie, Darren March, Michael Whitehouse
-
Patent number: RE41287Abstract: The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions.Type: GrantFiled: June 25, 1998Date of Patent: April 27, 2010Assignee: Promics Pty LimitedInventors: David Fairlie, Stephen Maxwell Taylor, Angela Monique Finch, Allan Wong